CorMedix Inc. Form 8-K January 19, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 19, 2016

CORMEDIX INC.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-34673 20-5894890

(State or Other

Jurisdiction of (Commission File (IRS Employer Incorporation) Number) Identification No.)

1430 U.S. Highway 206, Suite 200, Bedminster, NJ 07921

(Address of

Principal

Executive (Zip Offices) Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[&]quot; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: CorMedix Inc. - Form 8-K

••	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
_	

Edgar Filing: CorMedix Inc. - Form 8-K

Item 5.07. Submission of Matters to a Vote of Security Holders.

We held a special meeting of stockholders on January 19, 2016. At the meeting, the stockholders approved an amendment to the 2013 Stock Incentive Plan to increase the number of authorized shares of common stock reserved for issuance thereunder from 5,000,000 shares to 8,000,000 shares. The vote for the matter was 13,344,592 shares for, 6,880,338 shares against, 925,263 shares abstaining and no broker non-votes.

2

Edgar Filing: CorMedix Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: January 19, 2016 By: /s/ Randy Milby

Name: Randy Milby

Title: Chief Executive Officer

3